Of these, the co-expression of HER2/EGFRvIII, EGFRvIII/CD44, and EGFRvIII/CD44/HER2 were all associated with poorer overall survival [115] Tina Al-Janaby et al., 2025, The co-expression and prognostic significance of the HER-family members, EGFRvIII, CD44, CD109, and Claudin 18.2 in patients with adenocarcinoma, 3341 (in press)). Here, CD109 is linked to adenocarcinoma.